CDKN2A and hepatocellular carcinoma: In vitro experiments in hepatocellular carcinoma cell lines disclosed a higher sensitivity to ribociclib in cell lines with high protein expression of RB and low expression of cyclin inhibitor p16, compared with cells that had lower RB expression and high p16 expression [82] (Table 5).